The thymidylate synthase inhibitor ZD1694 potently inhibits murine and human cytomegalovirus replication in quiescent fibroblasts

Antiviral Research

Volumn 47, Issue 2, 2000, Pages 111-120

  Lembo, David ^a   Gribaudo, Giorgio ^a   Riera, Ludovica ^a   Mondo, Alessandra ^a   Cavallo, Rossana ^a   Angeretti, Alessandra ^a   Landolfo, Santo ^b  

^a UNIVERSITY OF TURIN   (Italy)

^b CNR   (Italy)

Author keywords

Antifolate; Cytomegalovirus; Ganciclovir; Thymidylate synthase; ZD1694

Indexed keywords

GANCICLOVIR; THYMIDINE; THYMIDYLATE SYNTHASE; THYMIDYLATE SYNTHASE INHIBITOR; TOMUDEX;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL CELL; ANTIBIOTIC RESISTANCE; ANTIVIRAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG INHIBITION; DRUG SCREENING; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; LUNG FIBROBLAST; MOUSE; MOUSE SALIVARY GLAND VIRUS; NONHUMAN; PRIORITY JOURNAL; VIRUS INHIBITION;

ANIMAL; ANTIVIRAL AGENTS; CELLS, CULTURED; CYTOMEGALOVIRUS; DNA, VIRAL; FIBROBLASTS; GANCICLOVIR; HUMAN; INHIBITORY CONCENTRATION 50; MICE; MUROMEGALOVIRUS; POLYMERASE CHAIN REACTION; QUINAZOLINES; SUPPORT, NON-U.S. GOV'T; THIOPHENES; THYMIDYLATE SYNTHASE; VIRUS REPLICATION;

EID: 0033825705     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(00)00096-6     Document Type: Article

References (36)

1. Baldanti F., Underwood M.R., Stanat S.C., Biron K.K., Chou S., Sarasini A., Silini E., Gerna G. Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow growth phenotype, while mutation in the UL97-encoded phosphotransferase confer ganciclovir resistance in three-double resistant human cytomegalovirus strains recovered from patients with AIDS. J. Virol. 70:1996;1390-1395.
2. Barredo J., Moran R.G. Determinants of antifolate cytotoxycity: folylpolyglutamate synthetase activity during cellular proliferation and development. Mol. Pharmacol. 42:1992;687-694.
3. Blackledge G. New developments in cancer treatment with the novel thymidylate synthase inhibitor raltitrexed ('Tomudex'). Br. J. Cancer. 77:1998;29-37.
4. Collaborative DHPG Treatment Study Group, 1986. Treatment of serious cytomegalovirus infections with 9-(1,3-dihydroxy-2-propoxymetyl)guanine in patients with AIDS and other immunodeficiencies. N. Engl. J. Med. 27, 801-805.
5. Dittmer D., Mocarski E.S. Human cytomegalovirus infection inhibits G1/S transition. J. Virol. 71:1997;1629-1634.
6. Drew W.L., Miner R.C., Busch D.F., Follansbee S.E., Gullet J., Mehalko S.G., Gordon S.M., Owen W.F., Matthews T.R., Bushless W.C., DeArmond B. Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infections. J. Infect. Dis. 163:1991;716-719.
7. Erice A., Chou S., Biron K.K., Stanat S.C., Balfour H.H., Jordan M.C. Progressive disease due to ganciclovir-resistant cytomegalovirus immunocompromised patients. N. Engl. J. Med. 320:1989;289-293.
8. Fleming G.F., Schilsky R.L. Antifolates: the new generation. Semin. Oncol. 19:1992;707-719.
9. Gariglio M., Foresta P., Sacchi C., Lembo M., Hertel L., Landolfo S. Suppression of high mobility group protein T160 expression impairs mouse cytomegalovirus replication. J. Gen. Virol. 78:1997;665-670.
10. Gerna G., Baldanti F., Zavattoni M., Sarasini A., Percivalle E., Revello M.G. Monitoring of ganciclovir sensitivity of multiple human cytomegalovirus strains coinfecting blood of an AIDS patient by an immediate-early antigen plaque assay. Antiviral Res. 19:1992;333-345.
11. Ho M. Cytomegalovirus Biology and Infection. 1991;Plenum Press, New York.
12. Jackman A.L., Gibson W. Polyglutamation of the thymidylate synthase inhibitor, ZD1694 (Tomudex) in normal mouse tissues. Proc. Am. Assoc. Cancer Res. 36:1995;376.
13. Jackman A.L., Jones T.R., Calvert A.H. Thymidylate synthase inhibitors: experimental and clinical aspects. Muggia F.M. Experimental and Clinical Progress in Cancer Chemotherapy. 1985;155-210 Martinus Nijhoff, Boston.
14. Jackman A.L., Taylor G.A., Gibson W., Kimbell R., Brown M., Calvert A.H., Jusdson I.R., Hughes L.R. ZD1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study. Cancer Res. 51:1991;5579-5586.
15. Jackman A.L., Farrugia D.C., Gibson W., Kimbell R., Harrap K.R., Sthephens T.C., Azab M., Boyle F.T. ZD1694 (Tomudex): a new thymidylate synthase inhibitor with activity in colorectal cancer. Eur. J. Cancer. 31A:1995b;1277-1282.
16. Jacobson M.A., Drew W.L., Feimberg J., O'Donnell J.J., Whitmore P.V., Miner R.D., Parenti D. Foscarnet therapy for ganciclovir resistant retinitis in patients with AIDS. J. Infect. Dis. 163:1991;1348-1351.
17. Johnson L.F. Regulation of thymidylate synthase gene expression in growth-stimulated cells. Hu V.W. The Cell Cycle: Regulators, Targets, and Clinical Applications. 1994;141-147 Plenum Press, New York.
18. Knox K.K., Drobyski W.R., Carrigan D.R. Cytomegalovirus resistant to ganciclovir and foscernet from a marrow transplant patient. Lancet. ii:1991;1292-1293.
19. Lalezari J.P. Cidofovir: a new therapy for cytomegalovirus retinitis. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 14:1997;S22-S26.
20. Lembo D., Angeretti A., Gariglio M., Landolfo S. Murine cytomegalovirus induces expression and enzyme activity of dihydrofolate reductase in quiescent cells. J. Gen. Virol. 78:1998;2803-2808.
21. Lembo D., Gribaudo G., Cavallo R., Riera L., Angeretti A., Hertel L., Landolfo S. Human cytomegalovirus stimulates cellular dihydrofolate reductase activity in quiescent cells. Intervirology. 42:1999;30-36.
22. Lembo D., Cavallo R., Cornaglia M., Mondo A., Hertel L., Angeretti A., Landolfo S. Overexpression of cellular dihydrofolate reductase abolishes the anticytomegaloviral activity of methotrexate. Arch. Virol. 144:1999;1397-1403.
23. Mar E.C., Patel P.C., Huang E.S. Effect of 9-(2-hydroxyethoxymethyl)guanine on viral-specific polypeptide synthesis in human cytomegalovirus infected cells. Am. J. Med. 73:1982;82-95.
24. Mar E.C., Cheng Y.C., Huang E.S. Effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine on human cytomegalovirus replication in vitro. Antimicrob. Agents Chemother. 24:1983;518-521.
25. Navalgund L.G., Rossana C., Muench A.J., Johnson L.F. Cell cycle regulation of thymidylate synthetase gene expression in cultured mouse fibroblasts. J. Biol. Chem. 255:1980;7386-7390.
26. Panadero A., Yin M.B., Voigt W., Rustum Y.M. Contrasting patterns of DNA fragmentation induced by thymidylate synthase inhibitors, ZD1694 and AG-331. Oncol. Res. 7:1995;73-81.
27. Pauwels R., Balzarini J., Baba M., Snoeck R., Schols D., Herdewijin P., Desmyter J., De Clerq E. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti.HIV compounds. J. Virol. Methods. 20:1988;309-321.
28. Pressacco J., Erlichman C. Combination studies with 3′-azido-3′-deoxythymidine (AZT) plus ZD1694. Cytotoxic and biochemical effects. Biochem. Pharmacol. 46:1993;1989-1997.
29. Rawlinson W.D., Farrell H.E., Barrell B.G. Analysis of the complete DNA sequence of murine cytomegalovirus. J. Virol. 70:1996;8833-8849.
30. Shanley J.D., Debs R.J. The folate antagonist, methotrexate, is a potent inhibitor of murine and human cytomegalovirus in vitro. Antiviral Res. 11:1989;99-106.
31. Studies of Ocular Complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group, 1994. Foscarnet-Ganciclovir cytomegalovirus retinitis trial. IV: visual outcomes. Ophthalmology 101, 1250-1261.
32. Suzuki S., Saneyoshi M., Nakayama C., Nishiyama Y., Yoshida S. Mechanism of selective inhibition of human cytomegalovirus replication by 1-β-D-arabinofuranosyl-5-fluorouracil. Antimicrob. Agents Chemother. 28:1985;326-330.
33. Suzuki S., Misra H.K., Wliebe L.I., Knaus E.E., Tyrrel D.L. A proposed mechanism for the selective inhibition of human cytomegalovirus replication by 1-β2′-deoxy-2′-fluoro-β-D- arabinofuranosyl)-5-fluorouracil. Mol. Pharmacol. 31:1987;301-306.
34. Wachsman M., Hamzeh F.M., Saito H., Lietman P.S. Anticytomegaloviral activity of methotrexate associated with preferential accumulation of drug by cytomegalovirus-infected cells. Antimicrob. Agents Chemother. 40:1996;433-436.
35. Wingard J.R., Stuart R.K., Saral R., Burns W.H. Activity of trifluoro thymydine against cytomegalovirus. Antimicrob. Agents Chemother. 20:1981;286-290.
36. Yin M.B., Guimaraes M.A., Zhang Z.G., Arredondo M.A., Rustum M.Y. Time dependence of DNA lesions and growth inhibitition by ZD1694, a new quinazoline antifolate thymidylate synthase inhibitor. Cancer Res. 52:1992;5900-5905.